placeholder image
C. M. Lockhart All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Patient characteristics and use for bevacizumab in ophthalmology and oncology in a distributed research network. 
    Journal of managed care & specialty pharmacy. 2025
  • Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States. 
    Journal of managed care & specialty pharmacy. 2024
  • Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. 
    Journal of Medical Economics. 2023
  • BBCIC Research Network analysis of first-cycle prophylactic G-CSF use in patients treated with high-neutropenia risk chemotherapy. 
    Journal of the National Comprehensive Cancer Network. 2021
  • Patient characteristics and utilization patterns of short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilars compared to their reference product. 
    Drugs - real world outcomes. 2021
  • Descriptive analysis of long- and intermediate-acting insulin and key safety outcomes in adults with type 2 diabetes mellitus. 
    Journal of managed care & specialty pharmacy. 2019
  • Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to evaluate patterns of care. 
    Journal of managed care & specialty pharmacy. 2019
    • Contact
    full name
  • C. M. Lockhart
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration